150 related articles for article (PubMed ID: 11410024)
41. [Calcium antagonists of the dihydropyridine type: pharmaceutical chemistry and molecular pharmacology].
Mannhold R
Pharm Unserer Zeit; 1995 Jun; 24(3):137-53. PubMed ID: 7610109
[No Abstract] [Full Text] [Related]
42. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Roy K; Pratim Roy P
Eur J Med Chem; 2009 Jul; 44(7):2913-22. PubMed ID: 19128860
[TBL] [Abstract][Full Text] [Related]
43. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberg-Marquardt algorithm.
Jalali-Heravi M; Asadollahi-Baboli M; Shahbazikhah P
Eur J Med Chem; 2008 Mar; 43(3):548-56. PubMed ID: 17602800
[TBL] [Abstract][Full Text] [Related]
44. Hybrid Docking-QSAR Studies of 1, 4-dihydropyridine-3, 5-Dicarboxamides as Potential Antitubercular Agents.
Rasouli Y; Davood A
Curr Comput Aided Drug Des; 2018; 14(1):35-53. PubMed ID: 28462696
[TBL] [Abstract][Full Text] [Related]
45. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine).
Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M
Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
Ogihara T; Kano T; Kakinuma C
Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
[TBL] [Abstract][Full Text] [Related]
47. [Derivatives of 1,4-dihydropyridines as "priviledged structures" and their pharmacological potential].
Żorniak M; Mitręga K; Krzemiński TF
Kardiol Pol; 2011; 69 Suppl 3():100-3. PubMed ID: 22125212
[TBL] [Abstract][Full Text] [Related]
48. [Interaction of 1,4-dihydropyridines with ion channels].
Veizerová L; Svetlík J; Kettmann V
Ceska Slov Farm; 2008 Apr; 57(2):58-62. PubMed ID: 18578414
[TBL] [Abstract][Full Text] [Related]
49. A comparison of methods for modeling quantitative structure-activity relationships.
Sutherland JJ; O'Brien LA; Weaver DF
J Med Chem; 2004 Oct; 47(22):5541-54. PubMed ID: 15481990
[TBL] [Abstract][Full Text] [Related]
50. 1,4-Dihydropyridine derivatives as calcium channel modulators: the role of 3-methoxy-flavone moiety.
Budriesi R; Bisi A; Ioan P; Rampa A; Gobbi S; Belluti F; Piazzi L; Valenti P; Chiarini A
Bioorg Med Chem; 2005 May; 13(10):3423-30. PubMed ID: 15848754
[TBL] [Abstract][Full Text] [Related]
51. The 1,4-dihydropyridine nucleus: a pharmacophoric template part 1. Actions at ion channels.
Triggle DJ
Mini Rev Med Chem; 2003 May; 3(3):215-23. PubMed ID: 12570837
[TBL] [Abstract][Full Text] [Related]
52. QSAR modeling for quinoxaline derivatives using genetic algorithm and simulated annealing based feature selection.
Ghosh P; Bagchi MC
Curr Med Chem; 2009; 16(30):4032-48. PubMed ID: 19747124
[TBL] [Abstract][Full Text] [Related]
53. Development of linear and nonlinear predictive QSAR models and their external validation using molecular similarity principle for anti-HIV indolyl aryl sulfones.
Roy K; Mandal AS
J Enzyme Inhib Med Chem; 2008 Dec; 23(6):980-95. PubMed ID: 18608761
[TBL] [Abstract][Full Text] [Related]
54. Comparison of QSAR models based on combinations of genetic algorithm, stepwise multiple linear regression, and artificial neural network methods to predict Kd of some derivatives of aromatic sulfonamides as carbonic anhydrase II inhibitors.
Maleki A; Daraei H; Alaei L; Faraji A
Bioorg Khim; 2014; 40(1):70-84. PubMed ID: 25898725
[TBL] [Abstract][Full Text] [Related]
55. Comparative QSAR- and fragments distribution analysis of drugs, druglikes, metabolic substances, and antimicrobial compounds.
Karakoc E; Sahinalp SC; Cherkasov A
J Chem Inf Model; 2006; 46(5):2167-82. PubMed ID: 16995747
[TBL] [Abstract][Full Text] [Related]
56. Interpreting computational neural network QSAR models: a measure of descriptor importance.
Guha R; Jurs PC
J Chem Inf Model; 2005; 45(3):800-6. PubMed ID: 15921469
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and 3D-QSAR study of 1,4-dihydropyridine derivatives as MDR cancer reverters.
Radadiya A; Khedkar V; Bavishi A; Vala H; Thakrar S; Bhavsar D; Shah A; Coutinho E
Eur J Med Chem; 2014 Mar; 74():375-87. PubMed ID: 24486418
[TBL] [Abstract][Full Text] [Related]
58. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
Dietz JD; Du S; Bolten CW; Payne MA; Xia C; Blinn JR; Funder JW; Hu X
Hypertension; 2008 Mar; 51(3):742-8. PubMed ID: 18250364
[TBL] [Abstract][Full Text] [Related]
59. Role of Topological, Electronic, Geometrical, Constitutional and Quantum Chemical Based Descriptors in QSAR: mPGES-1 as a Case Study.
Gupta A; Kumar V; Aparoy P
Curr Top Med Chem; 2018; 18(13):1075-1090. PubMed ID: 30027847
[TBL] [Abstract][Full Text] [Related]
60. Modeling the antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides using different chemometrics methods.
Garkani-Nejad Z; Ahmadi-Roudi B
Eur J Med Chem; 2010 Feb; 45(2):719-26. PubMed ID: 19959260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
